

**WHAT'S EMERGING  
IN INFLAMMATORY  
BOWEL DISEASE  
TREATMENT**

Joan Heatherington  
RN, MN, ACNP  
University of Calgary IBD Clinic

---

---

---

---

---

---

---

---

**OBJECTIVES**

- Review interpretation of trough and antibody levels
- Switching anti-TNF?
- Discuss positioning of IL12/23 inhibitors and alpha 4 beta 7's into clinical care

---

---

---


---

---

---

---

---



**MRS P**

- Crohn's ileal colitis diagnosed in 1995.
- 1997 and 2013 extensive resections. Jejeunal rectal anastomosis
- Past medications: 5asa, Imuran (pancreatitis), remicade (DI lupus), MTX
- Humira weekly initiated November 2012
- Malnourished, diarrhea, polyarthralgia's
- Ada level <0.024 Anti-Ada >2000
- Active disease endoscopically

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### NOVEL TREATMENT OPTION'S

- Simponi- Golimumab: TNF inhibitor (off label in Crohn's disease)
- Stelara- Ustikinumab: IL12/23 inhibitor (off label in Crohn's disease)
- Vedolizumab: alpha 4 beta 7 inhibitor (Currently not available: but coming)

---

---

---

---

---

---

---


---

---

---

### PURSUIT SC: GOLIMUMAB IN UC

Primary and secondary efficacy endpoints at Week 6



Sandborn WJ, et al. Gastroenterology 2013 Epub ahead of print. DOI: 10.1053/j.gastro.2013.06.010

---

---

---

---

---

---

---


---

---

---

### PURSUIT SC: MAINTENANCE RESULTS

Primary and major secondary endpoints at Week 54 among randomised responders



Sandborn WJ, et al. Gastroenterology 2013 Epub ahead of print. DOI: 10.1053/j.gastro.2013.05.048

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### VEDOLIZUMAB IS A NOVEL GUT-SELECTIVE ANTI-INFLAMMATORY BIOLOGIC

- Humanized monoclonal Ab that binds exclusively to the  $\alpha 4\beta 7$  integrin heterodimer
  - Does not bind to  $\alpha 4\beta 1$  or  $\alpha E\beta 7$  integrin<sup>1</sup>
- Contains a mutated Fc region, preventing elicitation of<sup>2</sup>
  - Complement-mediated cytotoxicity
  - Antibody-dependent cellular cytotoxicity
  - Cytokine release

FC, fragment crystallisable; mAb, monoclonal antibody; VCAM-1, vascular cell adhesion molecule-1.  
 1. Soler D, et al. *J Pharmacol Exp Ther* 2009;330:864-76; 2. Data on file.

---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---



**MRS. P**  
Consistent development of AB's with TNF inhibitors  
Elected to switch to IL12/23 inhibitor  
Follow-up endoscopy in 16 weeks

---

---

---

---

---

---

---

---

**SUMMARY**

- Emerging strategies are defining improved ways of managing patients with IBD
- New therapies provide us with more choice and greater treatment flexibility
- Our task is to use the right treatment in the right patient at the right time
  - Explore the evidence base
  - Understand best practice
  - Optimise your first biologic
  - Tailor treatment to patient needs

---

---

---

---

---

---

---

---